Figure 3.
AALL0434 4-year DFS by treatment arm and CNS status. (A) Arm A (C-MTX, no nelarabine): CNS-1, 91.4% ± 1.8% and CNS-2, 92.9% ± 3.0% (P = .1756). (B) Arm B (C-MTX with nelarabine): CNS-1, 91.8% ± 3.0% and CNS-2, 89.8% ± 6.1% (P = .6218). (C) Arm C (HD-MTX, no nelarabine): CNS-1, 87.6% ± 2.0% and CNS-2, 80.0% ± 5.1%; and CNS-3, 70.2% ± 5.8% (P = .0006). (D) Arm D (HD-MTX with nelarabine): CNS-1, 86.6% ± 3.6%; CNS-2, 80.0% ± 8.4%; and CNS-3, 93.1% ± 5.2% (P = .35). (E) Only patients with CNS-3: arm C (HD-MTX, no nelarabine) 70.2% ± 5.8% and arm D (HD-MTX with nelarabine) 93.1% ± 5.2% (P = .0151).

AALL0434 4-year DFS by treatment arm and CNS status. (A) Arm A (C-MTX, no nelarabine): CNS-1, 91.4% ± 1.8% and CNS-2, 92.9% ± 3.0% (P = .1756). (B) Arm B (C-MTX with nelarabine): CNS-1, 91.8% ± 3.0% and CNS-2, 89.8% ± 6.1% (P = .6218). (C) Arm C (HD-MTX, no nelarabine): CNS-1, 87.6% ± 2.0% and CNS-2, 80.0% ± 5.1%; and CNS-3, 70.2% ± 5.8% (P = .0006). (D) Arm D (HD-MTX with nelarabine): CNS-1, 86.6% ± 3.6%; CNS-2, 80.0% ± 8.4%; and CNS-3, 93.1% ± 5.2% (P = .35). (E) Only patients with CNS-3: arm C (HD-MTX, no nelarabine) 70.2% ± 5.8% and arm D (HD-MTX with nelarabine) 93.1% ± 5.2% (P = .0151).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal